Abstract
COPD is one of the top 10 causes of death worldwide. Omic technologies represent a “big-data” approach to more accurate describe key features of COPD and inform treatment strategies. Herein we explore metabolomic approaches to study biochemical changes in the sputum of COPD patients and volunteers (n=14) not diagnosed with a respiratory disease (CON).
Sputum samples were assessed by high resolution - Direct infusion mass spectroscopy (DI-MS) based in the Q Exactive hybrid quadrupole-Orbitrap was used to assess the sample’s metabolomes. COPD samples were shown to be distinct using PLS-DA from CON and the sources of variation were identified. Five key metabolites allowed the discrimination between COPD and CON samples with an AUC value of 99% (CI 100%- 0.943 %).
Three of the key metabolites were monoacylglycerides also stearic acid suggesting considerable changes in fatty processing in COPD. Other metabolites were involved in pathways involved in inflammatory mediation, bronchoconstriction and mucus secretion, known features of COPD. Ongoing working is assessing metabolomic changes at different GOLD stages, examining the impact of comorbidities and smoking status. We expect new insights that could improve the monitoring of COPD and its treatment.
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 322.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020